August 27, 2021 8:01am

Pre-open indications: SELLs: 1; BUYs: 3; Maintain SELL: 1

If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi defines the extenuating factors of share pricing.

Never leave an investor uninformed!

 

Dow futures are UP +0.19% (+68 points), S&P futures are UP +0.24% (+11 point) and NASDAQ futures are UP +0.30% (+47 points)

 

Stock futures rose on Friday ahead of the Federal Reserve’s annual Jackson Hole on Friday to taper or not and when?

European markets were subdues waiting for the words,

Asia-Pacific markets traded mixed where Chinese mainland shares rose.

 

Data Docket: Investors also expect a consumer sentiment reading to be released Friday morning.

 

Henry’omics:

The three major U.S. indexes closed Thursday’s regular trading session lower.

Friday, the three major stock averages are all set to close the week in the green; the Dow is up 0.3%, the S&P 500 is up 0.6% and the Nasdaq is 1.6% higher – to date.

As I have said, Afghanistan outcomes are weighing on investor sentiment.

 

If you didn’t know what happen at Friday night’s close and the quarter’s “number’s” impact, you won’t be prepared for today’s session:

 

  • The Nasdaq closed DOWN -95.05 points (-0.64%);
  • The IBB closed down -0.69% and XBI closed down -0.45%
  • Sector volume was LOW with 3 of the 9-upside having higher than the 3-month average volume with very LOW volume of 2 of 23-downside having higher than the 3-month average volume;
  • The CBOE Volatility Index (VVIX: INDEX) was up +2.05 points or =12.21% at 18.84
  • Wednesday’s percentage (%) of the 9-upside were +0.07% (MDXG) to +17.65% (BSTG) while the 23-downside -0.18% (RARE) to -4.65% (CLBS);

 

  • Q3/21: August: 10 positive and 9 negative close
  • July: 6 positives, 1 holiday and 15 negative closes

Q2/21:

  • June: 15 positive and 8 negative closes
  • May:  8 positive, 12 negative closes and 1 holiday
  • April: 11 negative and 10 positive closes

Q1/21:

  • March: 10 positive, 12 negative and 1 neutral closes
  • February: 9 positive, 10 negative closes and 1 holiday
  • January: 10 positive, 9 negative closes and 1 holiday

 

Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542  … to date:

 

Companies in my headlights – It’s your decision; I provide an idea and context:

The Biostage (BSTG) Chronicles - Maintaining Sell – notice how the shares trade with the “pump/promote”?

Biostage (BSTG) closed up again +$0.39 with 3,137 shares traded after Wednesday’s +$0.16 with 18,472 shares traded after Tuesday’s +$0.28 with 10,590 shares traded after Monday’s +$0.68 to $1.89 with 38,354 shares traded and last Friday’s -$0.07 to $1.21 with 570 shares traded.

Question#1: Being able to trade a stock doesn't mean it is worth the share price; an equity that has NO clinical trial after an approved 1.5-year-old IND.

MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.

 

Pre-open Indications:

BUY:

Editas Medicine (EDIT) closed down -$1.72 after Wednesday’s +$0.87, Tuesday’s -0.64 and Monday’s $4.98 with a positive +$0.01 or +0.02% pre-market indication,

CRISPR Therapeutics (CRSP) closed down again -$3.90 after Wednesday’s -$0.66 and Tuesday’s +$1.44 and has a positive +$1,12 or +0.92% pre-market indication;

Intellia Therapeutics (NTLA) closed down again -$3.99 after Wednesday’s -$3.86 and Tuesday’s +$4.26 and has a positive +$1.533 or +0.99% pre-market indication;

 

SELL:

bluebird bio (BLUE) closed down -$0.28 and has a negative -$0.31 or -173% pre-open indication,

 

The BOTTOM LINE: When you’re on a roller coaster, the only thing you can be sure of is you’ll end up back where you started

Investors should take short-term profits to cash-up for coming drifts!

Some earnings’ Reports Outstanding:

  • Applied Genetic Technologies (AGTC) – 9/8 reporting, Mesoblast (MESO), Pluristem (PSTI) and Pluristem (PSTI), ReNeuron (RENE.L)

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.